9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 23

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure,  To further characterize the safety profile of ZD1839 at a 250mg daily dose,  To estimate PFS (progression free survival), To estimate overall survival

Interventions: ZD1839,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 2008

Completion Date: April 2008

Last  Posted Date: June 6, 2012

Location:

Website Link: https://ClinicalTrials.gov/show/NCT00787410

Was this article helpful?
Dislike 0